EA201890629A1 - APPLICATION OF ANTIBODIES TO CD40 FOR THE TREATMENT OF LABOR JEFRACT - Google Patents

APPLICATION OF ANTIBODIES TO CD40 FOR THE TREATMENT OF LABOR JEFRACT

Info

Publication number
EA201890629A1
EA201890629A1 EA201890629A EA201890629A EA201890629A1 EA 201890629 A1 EA201890629 A1 EA 201890629A1 EA 201890629 A EA201890629 A EA 201890629A EA 201890629 A EA201890629 A EA 201890629A EA 201890629 A1 EA201890629 A1 EA 201890629A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
treatment
jefract
labor
application
Prior art date
Application number
EA201890629A
Other languages
Russian (ru)
Other versions
EA039944B1 (en
Inventor
Скотт Роналд Бродёр
Томас Б. Фриман
Джералд Генри Набозни
Мира Рамануджам
Пауль Шолль
Йюрген Штеффген
Original Assignee
Бёрингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бёрингер Ингельхайм Интернациональ Гмбх filed Critical Бёрингер Ингельхайм Интернациональ Гмбх
Priority claimed from PCT/US2016/049558 external-priority patent/WO2017040566A1/en
Publication of EA201890629A1 publication Critical patent/EA201890629A1/en
Publication of EA039944B1 publication Critical patent/EA039944B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

Настоящее изобретение относится к новым гуманизированным антагонистическим антителам к CD40 и терапевтическим и диагностическим методам и композициям применения этих антител для лечения и/или предотвращения волчаночного нефрита.The present invention relates to new humanized antagonistic antibodies to CD40 and therapeutic and diagnostic methods and compositions for using these antibodies for the treatment and / or prevention of lupus nephritis.

EA201890629A 2016-01-27 2016-08-31 Use of anti-cd40 antibodies for treatment of lupus nephritis EA039944B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662287587P 2016-01-27 2016-01-27
PCT/US2016/049558 WO2017040566A1 (en) 2015-09-01 2016-08-31 Use of anti-cd40 antibodies for treatment of lupus nephritis

Publications (2)

Publication Number Publication Date
EA201890629A1 true EA201890629A1 (en) 2018-09-28
EA039944B1 EA039944B1 (en) 2022-03-30

Family

ID=81077505

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890629A EA039944B1 (en) 2016-01-27 2016-08-31 Use of anti-cd40 antibodies for treatment of lupus nephritis

Country Status (1)

Country Link
EA (1) EA039944B1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
BRPI0510317A (en) * 2004-04-27 2007-10-16 Novartis Vaccines & Diagnostic antagonist anti-cd40 monoclonal antibodies and methods for their use
JP5027804B2 (en) * 2005-05-26 2012-09-19 シアトル ジェネティクス，インコーポレーテッド Humanized anti-CD40 antibodies and methods of use thereof
MEP39508A (en) * 2006-04-21 2011-02-10 Novartis Ag Antagonist anti-cd40 antibody pharmaceutical compositions
PT3178851T (en) * 2010-03-31 2020-07-17 Boehringer Ingelheim Int Anti-cd40 antibodies
WO2012149356A2 (en) * 2011-04-29 2012-11-01 Apexigen, Inc. Anti-cd40 antibodies and methods of use

Also Published As

Publication number Publication date
EA039944B1 (en) 2022-03-30

Similar Documents

Publication Publication Date Title
EA201990912A1 (en) ANTI-LAG-3 ANTIBODIES AND THEIR COMPOSITIONS
EA201891199A1 (en) COMPOSITIONS CONTAINING BACTERIAL STRAINS
EA201891202A1 (en) COMPOSITIONS CONTAINING BACTERIAL STRAINS
EA201891201A1 (en) COMPOSITIONS CONTAINING BACTERIAL STRAINS
EA201890050A1 (en) COMPOSITIONS CONTAINING BACTERIAL STRAINS
EA201890049A1 (en) COMPOSITIONS CONTAINING BACTERIAL STRAINS
EA201890048A1 (en) COMPOSITIONS CONTAINING BACTERIAL STRAINS
EA201890047A1 (en) COMPOSITIONS CONTAINING BACTERIAL STRAINS
EA201891083A1 (en) COMPOSITIONS OF ANTIBODIES TO CD38 FOR SCRAPTURE AND THEIR APPLICATION
EA201890131A1 (en) IMMUNOMODULATION AND TREATMENT OF SOLID TUMORS BY ANTIBODIES THAT SPECIFICALLY CONNECT CD38
EA201890325A1 (en) PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR APPLICATION FOR THE TREATMENT OF INFLAMMATORY DISEASES
EA201691541A1 (en) NEW ANTI-BAFF ANTIBODIES
EA201691857A1 (en) COMPOUNDS APPLICABLE AS IMMUNOMODULATORS
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
EA201691135A1 (en) NEW GLUTAMINASE INHIBITORS
EA201790273A1 (en) FLAGELLIN COMPOSITIONS AND THEIR APPLICATION
EA201691974A1 (en) ANTIBODIES AGAINST OX40 AND METHODS OF THEIR APPLICATION
PH12017501077A1 (en) Compositions and methods for antibodies targeting bmp6
PH12017501522A1 (en) Antibodies to tau and uses thereof
MX2018009325A (en) Compounds and methods of treating rna-mediated diseases.
EA201691521A1 (en) ANTIBODIES TO INTERLEUKIN-21
EA201792561A1 (en) ANTIBODIES AIMED ON MORPHOGENETIC BONE 9 PROTECTION (BMP9) AND METHODS OF THEIR APPLICATION
EA201790565A1 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF PREDICATIVE LESIONS OF THE SKIN
PH12018500445A1 (en) Use of anto-cd40 antibodies for treatment of lupus nephritis
SG10201908881PA (en) Fused bicyclic compounds for the treatment of disease